title: Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer.
abstract: BACKGROUND
  To evaluate feasibility and safety of induction three-drugs combination chemotherapy and concurrent radio-chemotherapy in stage IIIB NSCLC.
  
  
  METHODS
  Patients with stage IIIB NSCLC were treated with three courses of induction chemotherapy, cisplatin 50 mg/m(2), paclitaxel 125 mg/m(2) and gemcitabine 1000 mg/m(2) on days 1,8 of every 21 day cycle. Patients without distant progressive disease were then treated with radiotherapy and concurrent weekly gemcitabine (250 mg/m(2)). Toxicity and response of radio-chemotherapy treatment have been assessed.
  
  
  RESULTS
  Between Jan 01 and Nov 02, 46 patients were enrolled. Grade 3+ hematological and non-hematological toxicity during the induction phase were 41.3% and 13.1%, respectively. In 38 patients a Clinical Response or Stable Disease was recorded and these patients underwent to concurrent radio-chemotherapy. Grade 3+ hematological and non-hematological toxicities were 8.2% in this group. Further response was observed in 66% of patients. Overall median survival time was 17.8 months, with a 3-year survival rates of 23%.
  
  
  CONCLUSIONS
  Three-drugs induction chemotherapy and concurrent radio-chemotherapy with weekly gemcitabine in locally advanced stage IIIB NSCLC is feasible and safe.
authors.affiliation: Radiotherapy Unit, University Campus Bio-Medico, Via E. Longoni 49, 00155 Rome, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Trodella
authors.forename: F
authors.initials: F
authors.lastname: De Marinis
authors.forename: R M
authors.initials: RM
authors.lastname: D'Angelillo
authors.forename: S
authors.initials: S
authors.lastname: Ramella
authors.forename: A
authors.initials: A
authors.lastname: Cesario
authors.forename: S
authors.initials: S
authors.lastname: Valente
authors.forename: F
authors.initials: F
authors.lastname: Nelli
authors.forename: M R
authors.initials: MR
authors.lastname: Migliorino
authors.forename: S
authors.initials: S
authors.lastname: Margaritora
authors.forename: G M
authors.initials: GM
authors.lastname: Corbo
authors.forename: V
authors.initials: V
authors.lastname: Porziella
authors.forename: M
authors.initials: M
authors.lastname: Ciresa
authors.forename: F
authors.initials: F
authors.lastname: Cellini
authors.forename: S
authors.initials: S
authors.lastname: Bonassi
authors.forename: P
authors.initials: P
authors.lastname: Russo
authors.forename: E
authors.initials: E
authors.lastname: Cortesi
authors.forename: P
authors.initials: P
authors.lastname: Granone
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine